GEODE-II: Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Low-Dose Ribavirin QD in Patients with Genotype 1a Chronic Hepatitis C Virus Infection without Cirrhosis

被引：0
作者：
Poordad, Fred [1 ]
Sedghi, Shahriar [2 ]
Pockros, Paul J. [12 ]
Ravendhran, Natarajan [3 ]
Reindollar, Robert [4 ]
Lucey, Michael R. [5 ]
Epstein, Michael S. [6 ]
Bank, Leslie [7 ]
Bernstein, David E. [8 ]
Trinh, Roger [9 ]
Krishnan, Preethi [9 ]
Pilot-Matias, Tami [9 ]
Polepally, Akshanth R. [9 ]
Pothacamury, Rajvineeth K. [9 ]
Unnebrink, Kristina [10 ]
Martinez, Marisol [9 ]
Nelson, David R. [11 ]
机构：
[1] Univ Texas Hlth Sci Ctr San Antonio, Texas Liver Inst, San Antonio, TX 78229 USA
[2] Mercer Univ, Sch Med, Med & Surg, Macon, GA 31207 USA
[3] Digest Dis Associates, Baltimore, MD USA
[4] Piedmont Healthcare Carolinas Ctr Liver Dis, Statesville, NC USA
[5] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Gastroenterol Hepatol, Madison, WI USA
[6] Digest Disorders Associates, Anne Arundel Med Ctr, Annapolis, MD USA
[7] Reg Clin Res Inc, Endwell, NY USA
[8] Hofstra Northwell Sch Med, Manhasset, NY USA
[9] AbbVie Inc, N Chicago, IL USA
[10] AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany
[11] Univ Florida, Dept Med, Gainesvillle, FL USA
[12] Scripps Clin, Div Gastroenterol Hepatol, La Jolla, CA 92037 USA
来源：
HEPATOLOGY | 2016年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
872
引用
收藏
页码：431A / 432A
页数：2
相关论文
共 50 条
  • [41] Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis
    Chen, Chun-Hsien
    Chen, Chien-Hung
    Lin, Chih-Lang
    Lin, Chun-Yen
    Hu, Tsung-Hui
    Tung, Shui-Yi
    Hsieh, Sen-Yung
    Lu, Sheng-Nan
    Chien, Rong-Nan
    Hung, Chao-Hung
    Sheen, I-Shyan
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [42] An Open-Label, Multicenter Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin in US Veterans with Genotype 1 Chronic Hepatitis C Infection: Efficacy and Safety Results of TOPAZ-VA
    Fuchs, Michael
    Morgan, Timothy R.
    Charafeddine, Mariem
    Brau, Norbert
    Schmidt, Warren N.
    Kozal, Michael
    Naggie, Susanna
    Cheung, Ramsey
    Pilot-Matias, Tami
    Yu, Yao
    Richards, Kristine
    Mullally, Victoria
    Cohen, Daniel E.
    Monto, Alexander
    Toro, Doris H.
    HEPATOLOGY, 2016, 64 : 488A - 488A
  • [43] Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C
    Atsukawa, Masanori
    Tsubota, Akihito
    Koushima, Yohei
    Ikegami, Tadashi
    Watanabe, Kouji
    Shimada, Noritomo
    Sato, Shinichi
    Kato, Keizo
    Abe, Hiroshi
    Okubo, Tomomi
    Arai, Taeang
    Itokawa, Norio
    Kondo, Chisa
    Mikami, Shigeru
    Asano, Toru
    Chuganji, Yoshimichi
    Matsuzaki, Yasushi
    Iwakiri, Katsuhiko
    HEPATOLOGY RESEARCH, 2017, 47 (13) : 1429 - 1437
  • [44] Safety and Efficacy of Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir for Hepatitis C Virus Infection Across All Levels of Kidney Function
    Sise, Meghan E.
    KIDNEY INTERNATIONAL REPORTS, 2019, 4 (02): : 191 - 193
  • [45] Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis
    Wedemeyer, H.
    Craxi, A.
    Zuckerman, E.
    Dieterich, D.
    Flisiak, R.
    Roberts, S. K.
    Pangerl, A.
    Zhang, Z.
    Martinez, M.
    Bao, Y.
    Calleja, J. -L.
    JOURNAL OF VIRAL HEPATITIS, 2017, 24 (11) : 936 - 943
  • [46] Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir Co-Administered with Ribavirin in Adults with Genotype 4 Chronic Hepatitis C Infection and Cirrhosis (AGATE-I)
    Asselah, Tarik
    Hassanein, Tarek I.
    Qaqish, Roula B.
    Feld, Jordan J.
    Hezode, Christophe
    Zeuzem, Stefan
    Ferenci, Peter
    Pilot-Matias, Tami
    Yu, Yao
    Redman, Rebecca
    Mobashery, Niloufar
    HEPATOLOGY, 2015, 62 : 563A - 564A
  • [47] Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience
    Aygen, Bilgehan
    Demirturk, Nese
    Yildiz, Orhan
    Celen, Mustafa Kemal
    Celik, Ilhami
    Barut, Sener
    Ural, Onur
    Batirel, Ayse
    Mistik, Resit
    Simsek, Funda
    Asan, Ali
    Ersoz, Gulden
    Turker, Nesrin
    Bilgin, Huseyin
    Kinikli, Sami
    Karakecili, Faruk
    Zararsiz, Gokmen
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2020, 31 (04) : 305 - 317
  • [48] EFFICACY AND SAFETY OF OMBITASVIR, PARITAPREVIR/RITONAVIR, AND DASABUVIR WITHOUT RIBAVIRIN IN PATIENTS WITH HCV GENOTYPE 1B WITH OR WITHOUT COMPENSATED CIRRHOSIS: POOLED ANALYSIS ACROSS 5 CLINICAL TRIALS
    Welzel, T. M.
    Isakov, V.
    Trinh, R.
    Streinu-Cercel, A.
    Dufour, J. -F.
    Marinho, R. T.
    Moreno, C.
    Liu, L.
    Xie, W.
    Tatsch, F.
    Shulman, N.
    Craxi, A.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S824 - S824
  • [49] Exposure–Safety Response Relationship for Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III Studies
    Chih-Wei Lin
    Rajeev Menon
    Wei Liu
    Thomas Podsadecki
    Nancy Shulman
    Barbara DaSilva-Tillmann
    Walid Awni
    Sandeep Dutta
    Clinical Drug Investigation, 2017, 37 : 647 - 657
  • [50] Efficacy and Safety of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir Without Ribavirin in Patients with HCV Genotype 1b With or Without Compensated Cirrhosis: Pooled Analysis Across 5 Clinical Trials
    Welzel, Tania M.
    Isakov, Vasily
    Trinh, Roger N.
    Streinu-Cercel, Adrian
    Dufour, Jean-Francois
    Marinho, Rui T.
    Moreno, Christophe
    Liu, Li
    Xie, Wangang
    Tatsch, Fernando
    Shulman, Nancy S.
    Craxi, Antonio
    GASTROENTEROLOGY, 2016, 150 (04) : S1095 - S1095
12345